Skyhawk is committed to discovering, developing, and commercializing small molecule therapeutics that correct RNA splicing. We use our novel SkySTAR® platform (Skyhawk Small molecule Therapeutics for Alternative splicing of RNA) to develop drug candidates directed to targets for some of the world’s most intractable diseases including cancer, neurological conditions, and other “undruggable” targets against a wide range of conditions.